Syensqo and Allozymes sign Memorandum of Understanding to pioneer home and personal care biosolutions

The partnership will leverage the power of enzymes to deliver cleaner and high-performing biosolutions for home and personal care applications

Brussels, July 4, 2024 - Syensqo and Allozymes, a Singaporean enzyme engineering start-up, announce the signing of a Memorandum of Understanding (MOU) to leverage both companies strengths in biotechnology towards the development of advanced biosolutions for Home and Personal Care, in particular for the skin care market.

Allozymes stands out in the bio-engineering sector with its unique ultra-high throughput microfluidics platform for the engineering of enzymes and microbes. This platform enables the rapid and cost-effective development of biomanufactured ingredients and bioprocesses, setting a new standard for innovation and sustainability in the industry.

“By combining Allozymes technological capabilities with Syensqo's application and market access expertise, we are poised to create groundbreaking solutions that will not only benefit the home and personal care market but also contribute to a more sustainable future,” said Thomas Canova, head of Renewable Materials & Biotechnology growth platform at Syensqo.

This MOU marks an important milestone in Syensqo’s strategic agenda of rapidly expanding its beauty specialty ingredients portfolio based on biotechnology. It complements the company's recent acquisition of South Korean ceramides specialist JinYoung Bio, further solidifying its commitment to enabling sustainable and innovative care solutions.

“Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations. Together, we're setting a new standard for environmental stewardship," added Peyman Salehian, PhD, CEO and cofounder at Allozymes.

Reader enquiries

Rue de la Fusée 98
1130 Brussels





Notes for editors

About Syensqo
Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.

Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and healthcare applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Learn more at

About Allozymes 
Allozymes is a biotechnology company that applies its proprietary ultra-high-throughput platform technology to rapidly develop novel enzymes and unlock the bioeconomy across sectors. Leveraging this ultra-high screening power, Allozymes aims to build the largest enzyme data library in the world to address the current and future needs of building robust biosolutions.

Learn more at

Related images

Top row left to right: Ilham Kadri, CEO at Syensqo and Peyman Salehian, PhD, CEO, Co-founder at Allozymes.
Bottom row left to right: Jean-Guy Le-Helloco, Vice President Home & Personal Care at Syensqo and Akbar Vahidi, PhD, CTO, Co-founder at Allozymes. (Photo: Syensqo, PR029)





More news from